Provider action: Coverage and documentation guidance

Coverage of listed CPT and HCPCS vaccine and administration codes is contingent on meeting the policy's selection criteria and applicable clinical guidance (including ACIP recommendations). There are no step therapy requirements and no explicit prior authorization/denial trigger specified for these vaccine codes. Providers must document clinical rationale for vaccine selection consistent with ACIP guidance and patient-specific factors (age, pregnancy status, immunocompromise, chronic conditions, prior vaccine history, allergy history, LAIV contraindications and age limits, and HCT recipient considerations). Use ICD-10 code Z23 for vaccine encounter billing. LAIV (intranasal) has specific age and effectiveness contraindications per ACIP (e.g., not for certain ages, not recommended for some immunocompromised or pregnant patients); follow ACIP guidance when choosing LAIV. Required clinical documentation includes indication for vaccine, vaccine product and lot, route and site of administration, date, informed consent/counseling notes, and any relevant medical history affecting vaccine choice. No additional specific documentation beyond standard immunization record elements is mandated by the policy.

• Codes requiring coverage criteria: CPT and HCPCS vaccine and administration codes listed are covered only if selection criteria are met.
• Coverage tied to ACIP recommendations: Vaccine use and selection should follow current ACIP recommendations; vaccine choice may vary based on age, pregnancy, immunocompromise, and HCT status.
• LAIV contraindications: LAIV is contraindicated or not recommended for certain age groups, pregnant persons, and many immunocompromised persons; consult ACIP.
• No explicit authorization/denial trigger: Policy does not specify an automatic authorization or denial trigger solely based on coding.
• Use ICD-10 Z23: Use Z23 for encounter for immunization.
• Required clinical documentation: Indication, vaccine product and lot, route/site, date, informed consent/counseling, relevant medical history (allergy, prior vaccine reactions), and rationale for vaccine selection (including HCT recipient considerations).
• No step therapy requirements described.

Codes covered when selection criteria are satisfied

The CPT and HCPCS influenza vaccine and related administration codes listed in the policy are considered covered when the member meets the policy's selection criteria (age, ACIP recommendations, and other clinical considerations); verify and document that the chosen vaccine formulation is appropriate before submitting claims.

• Covered vaccine CPT examples: 90630, 90661, 90672, 90686, 90694.
• ICD-10 encounter code for immunization when selection criteria are met: Z23.

No prior authorization specified in excerpts; follow age-appropriate guidance

No specific prior authorization requirements for influenza vaccines are stated in the provided excerpts; providers should use age-appropriate formulations per ACIP guidance and follow any plan-specific prior authorization processes if separately required.

• Policy notes age-appropriate options (e.g., high-dose/adjuvanted vaccines for persons 65+), but does not list PA steps in these excerpts.

No prior authorization requirements described here

The policy excerpts do not describe any prior authorization requirements for the influenza vaccines or administration codes; confirm any plan-level authorization rules outside this CPB before proceeding.

No prior authorization specified in this section

This portion of the policy does not specify prior authorization requirements for influenza vaccination; providers should rely on ACIP age/formulation guidance and local plan procedures.

Consider LAIV age indication and historical effectiveness

LAIV (intranasal/FluMist) is indicated for persons aged 2 through 49 years but has had seasons when ACIP did not recommend its use due to reduced effectiveness; providers should consider age and historical effectiveness when selecting LAIV.

• LAIV4 approved for ages 2–49 years (FDA approval noted).
• ACIP recommended against LAIV4 use in 2016–17 and 2017–18 because of low effectiveness against certain H1N1 viruses.

Follow current ACIP guidance; LAIV history affected recommendations

ACIP recommendations about LAIV were influenced by observed reduced effectiveness in certain seasons; when choosing vaccine type, follow current ACIP guidance and consider clinical history and prior seasonal VE data.

• Data showed LAIV VE estimate of 3% in 2015–2016 among children versus 63% for IIV in that season.
• ACIP reinstated LAIV4 for 2018–19 after review; providers must follow the current ACIP recommendation.

Avoid LAIV in HCT recipients — use inactivated vaccine

Do not administer intranasal live influenza vaccine to hematopoietic cell transplant (HCT) recipients; use an effective inactivated vaccine alternative instead.

• Guidelines indicate LAIV should not be given to HCT recipients because an effective inactivated alternative exists.

No step therapy described

No step therapy requirements for influenza vaccination are described in the provided excerpts.

Use ICD-10 code Z23 for immunization encounters

When billing for an immunization encounter, use ICD-10 code Z23 (Encounter for immunization) when the member meets the policy's selection criteria.

• Use Z23 to indicate the visit was for immunization when the vaccine and member meet policy criteria.

Document age, allergy, pregnancy, immunocompromise, wheeze/GBS history

Document clinical details that support vaccine selection and appropriateness, including patient age, history of allergies (including severity of egg allergy), pregnancy status, immunocompromising conditions, recent wheeze/asthma history in young children, and any prior Guillain-Barré syndrome.

• For egg-allergic persons, note reaction type (urticaria only versus more severe) and, if using a vaccine other than ccIIV4 or RIV4 for severe egg reactions, document administration in a setting equipped to manage severe allergic reactions.
• Document contraindications to LAIV (e.g., age <2 or >50 years, pregnancy, immunocompromised status, asthma/wheezing, prior GBS).

No additional documentation requirements stated here

The provided excerpt does not list additional specific documentation requirements beyond standard clinical documentation; ensure records support vaccine choice and administration.

Providers responsible for medical advice and treatment

Participating providers are independent contractors and are solely responsible for medical advice and treatment of members; ensure clinical decisions and documentation reflect this responsibility.

• Aetna's CPB is informational and does not substitute for the treating provider's clinical judgment.

LAIV covered only for ages 2–49 years per ACIP/medical necessity

Coverage for intranasal live attenuated influenza vaccine is limited to members aged 2 through 49 years and is tied to ACIP recommendations and medical necessity; billing for LAIV outside that age range or contrary to ACIP guidance may be denied.

• Confirm member age (2–49 years) and ACIP appropriateness before administering and billing for LAIV.

Do not give LAIV to persons with contraindications — risk of denial

Do not administer LAIV to persons with listed contraindications (including children <2 years, adults >50 years, pregnant or nursing women, the immunocompromised, patients with asthma or recent wheeze, history of GBS after prior influenza vaccination, or severe allergy to vaccine components); administration in these situations is inappropriate and likely to be denied.

• Contraindications explicitly include: age under 2 or over 50, pregnancy, immunocompromise, chronic heart or lung disease (including asthma), recent wheezing in children 2–4 years, prior GBS, and severe allergies to egg, chicken proteins, gentamicin, gelatin, arginine, or other LAIV components.

No explicit authorization or billing triggers in excerpts

No explicit authorization or billing triggers are presented in the cited document segments; verify plan-specific billing and authorization rules if applicable.

No specific authorization or denial triggers stated

The provided policy segments do not specify particular authorization or denial triggers; ensure vaccination follows ACIP recommendations and document medical necessity to reduce risk of claim denial.

CPB is informational and not a contract — verify coverage

This Clinical Policy Bulletin is a partial, general description of plan benefits and does not constitute a contract; providers should apply clinical judgment and confirm coverage details with the payer.